Recombinant Human CTSD Protein，His

CTSD, or Cathepsin D, is a lysosomal aspartyl protease that plays a crucial role in various physiological processes, including protein degradation, autophagy, and antigen presentation. Its dysregulation has been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases, making it a significant target for therapeutic research. The study of CTSD has gained momentum due to its association with tumor progression and metastasis, where it may enhance cancer cell invasion and promote immune evasion. In particular, researchers have focused on the characterization of recombinant CTSD protein to understand its structure-function relationships better and its substrate specificity. The recombinant protein production allows for the generation of large quantities of CTSD for in vitro and in vivo studies, facilitating the exploration of its enzymatic mechanisms and potential inhibitors. Advances in molecular biology techniques, including genetic engineering and protein purification methods, have made it possible to produce high-quality recombinant CTSD. The insights gained from these studies not only advance our understanding of CTSD's biological roles but also pave the way for the development of novel therapeutic strategies aimed at modulating its activity in disease contexts. Overall, CTSD research holds promise in identifying new biomarkers and pharmaceutical targets, contributing to more effective treatments for various health conditions.